X

Drug Profile

Research programme: neurological disorder therapeutics - GlaxoSmithKline/Icagen

Latest Information Update: 24 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Icagen, Inc.
Developer GSK; Icagen, Inc.
Class Small molecules
Mechanism of Action Membrane protein modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Neurological disorders

Most Recent Events

21 Dec 2021 Icagen and GlaxoSmithKline expand collaboration and license agreement for the development of small molecule therapeutics for the treatment of neurological disorders
24 Dec 2020 Icagen and GlaxoSmithKline enter into a collaboration and license agreement for the development of small molecule therapeutics for the treatment of neurological disorders
21 Dec 2020 Early research in Neurological disorders in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com